TAGLIAZUCCHI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.867
NA - Nord America 3.098
EU - Europa 2.898
SA - Sud America 437
AF - Africa 91
OC - Oceania 13
Totale 10.404
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.000
CN - Cina 1.252
SG - Singapore 1.141
IT - Italia 1.127
DE - Germania 427
VN - Vietnam 387
HK - Hong Kong 352
BR - Brasile 326
SE - Svezia 276
GB - Regno Unito 232
KR - Corea 215
RU - Federazione Russa 155
FR - Francia 133
FI - Finlandia 113
ID - Indonesia 97
IN - India 90
ES - Italia 65
NL - Olanda 60
CA - Canada 56
JP - Giappone 49
IQ - Iraq 43
CH - Svizzera 42
LT - Lituania 39
PL - Polonia 37
BD - Bangladesh 36
IE - Irlanda 35
AR - Argentina 34
BE - Belgio 28
ZA - Sudafrica 28
MX - Messico 25
PK - Pakistan 22
TR - Turchia 22
AT - Austria 20
UA - Ucraina 19
CL - Cile 17
MY - Malesia 17
UZ - Uzbekistan 17
EC - Ecuador 16
IR - Iran 15
SA - Arabia Saudita 15
MA - Marocco 13
TW - Taiwan 13
CZ - Repubblica Ceca 12
PH - Filippine 12
PY - Paraguay 12
VE - Venezuela 12
AE - Emirati Arabi Uniti 11
KE - Kenya 11
TN - Tunisia 11
BG - Bulgaria 10
CO - Colombia 10
AU - Australia 9
GR - Grecia 9
ET - Etiopia 7
NP - Nepal 7
TH - Thailandia 7
DK - Danimarca 6
JO - Giordania 6
LI - Liechtenstein 6
NO - Norvegia 6
RO - Romania 6
RS - Serbia 6
BY - Bielorussia 5
DZ - Algeria 5
EG - Egitto 5
JM - Giamaica 5
KZ - Kazakistan 5
MO - Macao, regione amministrativa speciale della Cina 5
UY - Uruguay 5
AL - Albania 4
AZ - Azerbaigian 4
CR - Costa Rica 4
IL - Israele 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
PE - Perù 4
PT - Portogallo 4
BH - Bahrain 3
GE - Georgia 3
HU - Ungheria 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
SN - Senegal 3
DO - Repubblica Dominicana 2
EE - Estonia 2
GH - Ghana 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NG - Nigeria 2
PS - Palestinian Territory 2
SV - El Salvador 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
Totale 10.394
Salva come PNG Salva come JPEG
Città #
Singapore 709
Santa Clara 654
Hefei 613
Ashburn 371
Hong Kong 339
San Jose 326
Seoul 196
Modena 186
Frankfurt am Main 167
Ho Chi Minh City 141
London 136
Chandler 134
Nyköping 113
Beijing 106
New York 99
Bologna 98
Council Bluffs 96
Los Angeles 96
Jakarta 81
Hanoi 80
The Dalles 76
Helsinki 75
Milan 62
Munich 61
Parma 55
Reggio Emilia 52
Moscow 47
Boardman 43
Lauterbourg 43
Shanghai 42
Chicago 37
Fairfield 36
Orem 36
São Paulo 36
Kent 33
Warsaw 30
Dublin 29
Buffalo 28
Dallas 27
Houston 25
Amsterdam 24
Formigine 24
Seattle 24
Lappeenranta 23
Rome 22
Madrid 21
Zurich 21
Tokyo 20
Padova 19
Da Nang 18
Princeton 18
Nuremberg 17
San Diego 17
Stockholm 17
Turin 17
Chennai 16
Piacenza 16
Leuven 15
Phoenix 15
Wilmington 15
Boston 14
Salt Lake City 14
Sassuolo 14
Tashkent 14
Barcelona 13
Decatur 13
Denver 13
Johannesburg 13
Manchester 13
Paris 13
Düsseldorf 12
Hangzhou 12
Osnabrück 12
Perugia 12
Portsmouth 12
Ravenna 12
Toronto 12
Vienna 12
Atlanta 11
Baghdad 11
Cambridge 11
Ferrara 11
Guangzhou 11
Ottawa 11
Poplar 11
Rio de Janeiro 11
Santiago 11
Brooklyn 10
Brussels 10
Haiphong 10
Hamburg 10
Mexico City 10
Nairobi 10
Redondo Beach 10
Tehran 10
Turku 10
Washington 10
Woodbridge 10
Biên Hòa 9
Montreal 9
Totale 6.450
Salva come PNG Salva come JPEG
Nome #
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 304
Designing selective Cys-ligands to unpair the binding of the Human Transcription Enhancer Associated Domain 4 (hTEAD-4) with its modulators to halt cancer cell growth 277
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 260
Exploiting Forster Resonance Energy Transfer (FRET) in the characterization of YAP:TEAD complex disruption 257
design, synthesis and biological evaluation of novel YAP:TEAD complex disruptors for thetreatment of colorectal cancer 234
A toolbox of biophysical and analytical assays helps to confirm the activity of novel hTS dimer disrupters (Ddis) with anticancer properties 232
Development of a novel class of YAP:TEAD interface-3 molecular disruptors to treat colorectal carcinoma 227
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 223
A dual-Omics approach to identify the modulated proteins/genes in THP-1 cells infected with different drug resistant L. infantum clinical isolates. 219
Applying optical tweezers technology to reveal Thymidylate Synthase interactions with its consensus mRNA 213
LC-MS serum proteomics reveals a panel of proteins prognostic of positive responsiveness to bevacizumab therapy in late-stages ovarian cancer patients 213
Repurposing the trypanosomatidic gsk kinetobox for the inhibition of parasitic pteridine and dihydrofolate reductases 210
Current Treatments to Control African Trypanosomiasis and One Health Perspective 207
Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library 205
Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase 203
LC-MS/MS Helps Characterizing THP-1 Cells Proteome After Infection with Drug Resistant Leishmania Strains 201
Advances in the set-up of a fluorescence- anisotropy assay for the search of novel inhibitors of the tead-4 complexes 201
Coupling a microwave-assisted process with HPLC-ELSD for the extraction, purification and analysis of bioactive policosanols from beeswax 200
Targeting the dimer-monomer equilibrium of thymidylate synthase, to accelerate protein degradation and cancer cell growth inhibition 197
Lead optimization of human thymidylate synthase dimer disrupters: from computational studies to evaluation of their biological profiles 196
Structural bases for the synergistic inhibition of human thymidylate synthase and ovarian cancer cell growth by drug combinations 191
Lead-optimization process and characterization of the dissociative effect applied to new dimer disrupters of human Thymidylate Synthase 186
Exploring thymidylate synthase mRNA binding site 1 and human TS protein interaction with optical tweezers and bicistronic expression assay 184
Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation 184
Characterization and Valorization of the Agricultural Waste Obtained from Lavandula Steam Distillation for Its Reuse in the Food and Pharmaceutical Fields 184
UHPLC-MS/MS screening of the hTEAD surface for the identification of novel allosteric inhibitors with anticancer activity 180
Integrating MS proteomics in the Medicinal Chemistry pipeline as powerful tool to overcome drug resistance issues in colorectal cancer 178
The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents 177
Precision medicine through proteomics studies in drug resistant colorectal cancer 177
Advancing sustainable drug development: comparative preclinical study of H80 and Miltefosine using imaging and proteomics 176
EXPLOITING THE OPTICAL TWEEZER, A SINGLE MOLECULE TECHNOLOGY, TO REVEAL THYMIDYLATE SYNTHASE INTERACTIONS WITH ITS CONSENSUS mRNA 174
Development of a sensitive biochemical tool to assess the expression levels of recombinant ectopic proteins in in vitro engineered cellular systems 173
Identification of Innovative Folate Inhibitors Leveraging the Amino Dihydrotriazine Motif from Cycloguanil for Their Potential as Anti-Trypanosoma brucei Agents 173
Cellular uptake and metabolic degradation of a conjugate of folic acid with an anticancer peptide targeting the human Thymidylate synthase enzyme 171
Exploiting the Optical Tweezer technology to reveal thymidylate synthase interactions with its consensus mRNA 170
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective 168
Expression, purification, and characterization of Transcriptional Enhancer Associated Domain (hTEAD4), a promising target for anticancer agents 167
Biochemical characterization of the feedforward loop between CDK1 and FOXM1 in epidermal stem cells 166
Insights into host-target interaction from the proteome modulation analysis through untargeted LC-MS/MS Proteomics of drug resistant L infantum-THP1 infected cells 164
Leveraging proteomic, bioinformatic and ecotoxicology models to select new targets overcoming L. Infantum drug resistent 162
LC-MS/MS proteomics for the rapid and selective screening of drug resistances in Leishmania infantum clinical isolates 161
Deciphering Host–Parasite Interplay in Leishmania Infection through a One Health View of Proteomics Studies on Drug Resistance 159
Label-Free Mass Spectrometry Proteomics Reveals Different Pathways Modulated in THP-1 Cells Infected with Therapeutic Failure and Drug Resistance Leishmania infantum Clinical Isolates 158
Investigating the mechanism of action of the antiparasitic agent H80 through imaging techniques 157
One Health Approach in Drug Discovery for Leishmaniasis by Targeting Calpain cys-protease. 146
Optimization of chemical-biological tools for characterizing the activity of dissociative inhibitor of human thymidylate synthase 146
Drug discovery of pyrazolo-piperidinone inhibitors targeting YAP:TEAD interaction and development of a fluorescence anisotropy assay for high-throughput screening 145
Discovery of guanidino-containing benzimidazoles as novel antifolates for Trypanosomiasis 142
MS Proteomics And Biochemical Characterization Of Thymidylate Synthase Dimer Destabilizer E7 To Halt Colorectal Carcinoma 139
Development of guanidino-containing benzimidazoles as novel folate enzymes inhibitors for the treatment of Human African Trypanosomiasis 136
integrazione della proteomica mediante spettrometria di massa nel processo di Drug Discovery come strumento innovativo per superare la farmacoresistenza 131
Promoting A Sustainable Medicinal Chemistry Approach With The Cost Action CA21111 - One Health Drugs Against Parasitic Vector Borne Diseases In Europe And Beyond 130
Leveraging proteomics, bioinformatics, and ecotoxicology models to select new targets overcoming L infantum drug resistance. 127
Targeting of the Cysteines Surface domain of the Transcriptional Enhancer Associate Domain (TEAD) for anticancer drug discovery 119
Proteomic contribution to the omic path for the identification of novel drugs overcoming resistance in Leishmaniasis. 118
Structural insight into YAP-TEAD4 protein-protein interactions as target for cancer treatment 116
Preclinical investigation of H80 compared to miltefosine: imaging and proteomics for sustainable drug development 104
Development of a fluorescent anisotropy displacement assay for the optimization of YAP:TEAD molecular disrupters with anticancer activity 85
IDENTIFICATION OF PYRAZOLO-PIPERIDINONE DERIVATIVES TARGETING YAP-TEAD INTERFACE 3 AS ANTICANCER AGENTS THROUGH INTEGRATED VIRTUAL SCREENING AND MASS SPECTROMETRY PROTEOMICS 73
Totale 10.476
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.587
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.587
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 0 0 0 0 10 11 30
2021/2022369 26 12 2 2 2 47 18 32 50 41 85 52
2022/2023859 87 69 30 61 76 71 85 99 122 32 73 54
2023/20241.302 62 78 87 73 321 86 84 104 37 40 181 149
2024/20253.270 112 46 129 199 556 465 211 245 329 143 409 426
2025/20264.622 473 319 445 613 638 285 674 247 447 481 0 0
Totale 10.476